Komori
Treasury Stock4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding the Decision on Matters Concerning the Acquisition of Treasury Shares

Mochida Pharmaceutical decided to acquire up to 530,000 treasury shares through market purchases from 18 May to 18 December 2026, for a total purchase price of up to ¥2 billion. The acquisition limit is equivalent to 1.50% of the total number of issued shares excluding treasury shares.

Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
530000
Shares (maximum)
Wording
Conditional
How definitive the wording is.

Resolution on acquisition limit

Resolved 30 March 2026Market purchases on the Tokyo Stock Exchange
Total acquisition price¥2,000,000,000 (maximum)
Maximum number of shares to be acquired530,000 shares (maximum)The Company's common shares
1.5%Maximum number that can be acquired

The full horizontal line represents all issued shares, with marks at 10% intervals. The colored section represents the percentage stated in the resolution as the maximum proportion that may be repurchased under it.
This is a limit, and does not mean that the company will buy back all of it. The amount actually acquired will be shown in a later disclosure on the status of the acquisition of treasury shares.

Acquisition period

From 18 May 2026 (Monday) to 18 December 2026 (Friday)

Reason for acquisition

To mitigate the impact of this offering on the supply and demand of the Company's shares, enhance shareholder returns, improve capital efficiency, and pursue agile capital policies in response to changes in the Company's operating environment

Reference (number of shares stated in the document)
Current number of treasury shares940,273 shares (as of 28 February 2026)
Total number of issued shares35,449,727 shares (as of 28 February 2026, excluding treasury shares)
Resolution on acquisition limit
ItemDetails
Class of shares to be acquiredThe Company's common shares
Maximum number of shares to be acquired530,000 shares (maximum)
Percentage of total issued shares1.50%
Total acquisition price¥2,000,000,000 (maximum)
Acquisition periodFrom 18 May 2026 (Monday) to 18 December 2026 (Friday)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Reason for acquisitionTo mitigate the impact of this offering on the supply and demand of the Company's shares, enhance shareholder returns, improve capital efficiency, and pursue agile capital policies in response to changes in the Company's operating environment
Resolution date30 March 2026
Current number of treasury shares940,273 shares (as of 28 February 2026)
Total number of issued shares35,449,727 shares (as of 28 February 2026, excluding treasury shares)
Items this document does not state (6)
Number of shares to be retiredPercentage of total issued shares before retirementScheduled retirement dateTotal number of issued shares after retirementChange in acquisition periodChange in acquisition limit

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To mitigate the impact of this offering on the supply and demand of the Company's shares, enhance shareholder returns, improve capital efficiency, and pursue agile capital policies in response to changes in the Company's operating environment.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Decision on Matters Concerning the Acquisition of Treasury Shares | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori